Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan's 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024.
- Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan's 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024.
- Sach’s 20th Annual Biotech in Europe Forum, held in Basel, Switzerland, on September 25-26, 2024:
Presentation on September 25, at 11:40 am (CEST), in the Ruby Room. - Both posters will be presented during Poster Session II on Wednesday 23 October, 1:30 pm to 3 pm (CEST).
- Atamyo has rights to the LICA-1 capsid for cardiomyopathies indications.